摘要
目的探讨应用小剂量与常规剂量米托蒽醌+足叶乙甙+阿糖胞苷治疗老年急性髓系白血病(AML)的疗效。方法将42例老年AML患者分为两组,治疗组用米托蒽醌5mg/d,静脉滴注,第1~3天;足叶乙甙100mg/d,口服,第1~5天;阿糖胞苷100~150mg/d,第1~7天,静脉滴注。对照组米托蒽醌10mg/d,第1~3天;足叶乙甙100mg/d,静脉滴注,第1~5天;阿糖胞苷150~200mg/d,第1~7天,静脉滴注。结果治疗组完全缓解(CR)率57.1%,总有效率80.9%,对照组CR率52.4%,总有效率76.2%。两组CR率差异无显著性(P〉0.05)。治疗组粒细胞缺乏发生率、粒细胞缺乏持续时间及发热持续时间均低于对照组,差异有显著性(P〈0.05)。结论小剂量米托蒽醌+足叶乙甙+阿糖胞苷治疗老年急性髓系白血病疗效确切,毒副作用少。
Objective To evaluate the efficacy of low dose and conventional dose of mitoxantrone (MTZ, M), etoposide (V-p16, E) and cytarabine (Ara-c, A) in the treatment of acute myelogenous leukemia (AML) in elderly. Methods Forty-two old patients cases with AML were randomly divided into the low dose MEA group (treatment group) and conventional MEA group (control). Twenty-one cases were treated with the low dose MEA (M 5 mg/d iv, 1-3 d; Vpl6 100 mg/d po, 1-5 d; Ara-c 100-150 mg/d iv, ql2h, 1-7d). Twenty-one cases were treated with conventional MEA ( M 10 mg/d iv,1-3 d;Vpl6 100 mg/d iv, 1- 5 d;Ara-c 150-200 mg/d iv, ql2h, 1-7d ). Results Complete remission (CR) rate was 57. 1% and the total effective rate was 80.9% in the treatment group; CR rate was 52. 4% and total effective rate was 76.2% in control group. CR had no significant difference between the two groups (P 〉 0. 05). Agranulocytosis rate and duration, and fever duration in the low dose MEA group were lower than those in the control group (P 〈0. 05). Conclusion The low dose MEA is effective in treatment of AML in elderly and the adverse effect is low.
出处
《中国肿瘤临床与康复》
2008年第2期158-159,162,共3页
Chinese Journal of Clinical Oncology and Rehabilitation